StimCardio Secures $30 Million Series A Financing to Advance Wearable Atrial Fibrillation Therapy
StimCardio, a clinical-stage medical device company, has closed an oversubscribed $30 million Series A financing round. The funding was led by Metis Medtech, with participation from Catalyst Health Ventures and various strategic investors. The capital is earmarked to fund the NeuroPulse 2 pivotal study and prepare for a De Novo submission to the U.S. Food and Drug Administration (FDA). The company's lead product, Rhyvive™, is an investigational wrist-worn wearable designed to provide non-invasive median nerve stimulation (MNS). Positioned as an adjunctive therapy to catheter ablation, the device aims to reduce atrial fibrillation (AF) recurrence by modulating autonomic nervous system pathways from a patient's home. This development addresses a significant clinical gap in cardiac electrophysiology, where 30% to 40% of patients experience AF recurrence following initial ablation procedures. StimCardio seeks to establish non-invasive neuromodulation as a new therapeutic category for the approximately 59 million people living with AF globally.
Topics: Atrial Fibrillation Clinical Trials Medical Device Series A financing